PROLONG Study

D-Dimer Microchapters
Home
Patient information
Overview
Historical Perspective
Physiology
Clinical Correlation
Causes of High D-dimer
Diagnostic Role in Thromboembolism
Prognostic Role in Mortality
Prognostic Role in Thromboembolism Occurence
Prognostic Role in Thromboembolism Recurrence
Prognostic Role in Non-Thromboembolism
Clinical Trials
Landmark Trials
Case #1
PROLONG Study On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of PROLONG Study All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on PROLONG Study
CDC on PROLONG Study
PROLONG Study in the news
Blogs on PROLONG Study
Directions to Hospitals Treating D-dimer
Risk calculators and risk factors for PROLONG Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Official Title

D-Dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized “Prolong” Study

Objective

The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain. The present study addresses the possible role of the D-dimer test in assessing the need for continuation of anticoagulation. The study aims at assessing whether D-dimer assay may have a role in guiding the duration of anticoagulation in these patients.

Sponsor

St. Orsola Hospital

Timeline

Timeline
Start Date	September 2002
End Date	Not provided
Status	Completed

The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00264277.

Study Description

Study Description
Study Type	Interventional
Study Phase	Phase 4
Study Design
Allocation	Randomised
Endpoint	Safety/Efficacy Study
Interventional Model	Parallel Assignment
Masking	Open Label
Study Details
Primary Purpose	Treatment
Condition	Deep Vein Thrombosis Pulmonary Embolism
Intervention	Vitamin K antagonist (Coumarin anticoagulants)
Study Arms	Not provided
Population Size	600

The previous information was derived from ClinicalTrials.gov on 09/20/2013 using the identification number NCT00264277.

Eligibility Criteria

Inclusion Criteria

• Age > 18 years
• After a first documented idiopathic proximal deep vein thrombosis and/or pulmonary embolism
• After at least 3 months of oral anticoagulation
• After written informed consent

Exclusion Criteria

• If the Venous thromboembolism occurred:
  • During pregnancy or puerperium
  • After recent (i.e. within three months) fracture or plaster casting of a leg,
  • After immobilization with confinement to bed for three consecutive days
  • After surgery with general anesthesia lasting longer than 30 minutes
• Patients with:
  • Active cancer
  • Antiphospholipid antibody syndrome
  • Antithrombin deficiency
  • Serious liver disease or renal insufficiency (creatininemia > 2 mg/dL),
  • Other indications for anticoagulation or contraindications for this treatment
  • Limited life expectation
• Patients who live too far from the clinical center

Outcomes

Primary Outcomes

• Confirmed recurrent proximal deep vein thrombosis and/or pulmonary embolism at 18 months follow up
• Confirmed major bleeding events at 18 months follow up

Secondary Outcomes

Not provided